Thiazole Compounds Inducing UCP1 Expression in White Adipose Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current agents for inducing browning of white adipose tissue (WAT) to enhance thermogenesis and treat metabolic disorders like obesity and diabetes often have strong side effects, necessitating the development of safer and more effective compounds.
Innovation Solution
A series of compounds, including 3-(2-(pyridin-2-ylamino)thiazol-4-yl)benzonitrile and other thiazole derivatives, are developed to induce UCP1 expression and promote browning of WAT, which can be administered in various forms such as oral tablets, injectable solutions, or topical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional browning agents (such as β3-adrenergic agonists, prostaglandins, irisin, FGF21) are used to induce UCP1 expression and promote WAT browning, then thermogenesis and metabolic benefits are improved, but strong side effects occur
Solution Approach 1:
The patent modifies the chemical structure of known browning agents by introducing specific substituents (R1-R6 groups) at defined positions of the core molecular scaffold. This structural parameter change allows optimization of both browning efficacy and safety profile, reducing side effects while maintaining UCP1 induction capability. The systematic variation of substituent groups enables fine-tuning of the compound's biological activity and selectivity.
Solution Approach 2:
The invention develops a series of hybrid compounds combining features of different known browning agents (prostaglandins, irisin, FGF21) into a unified molecular scaffold with thiazole core. This composite approach integrates the beneficial effects of multiple agents while eliminating their individual side effects, creating a new class of compounds with improved safety and efficacy profiles for inducing WAT browning.
2Productivity
If existing browning agents are administered to achieve therapeutic effects for obesity and diabetes, then metabolic disorder treatment is improved, but safety and tolerability worsen
Solution Approach 1:
The patent employs compounds that selectively target specific pathways involved in WAT browning (UCP1 expression, mitochondrial biogenesis) without excessively activating other physiological systems. This partial action approach achieves sufficient metabolic benefit for treating obesity and diabetes while avoiding the excessive activation that causes side effects with conventional agents.
Solution Approach 2:
The novel compounds act as intermediary agents that indirectly promote browning through coordinated activation of multiple downstream pathways (AMPK, PGC-1α, UCP1) rather than directly forcing UCP1 expression. This intermediary mechanism provides a more physiological and safer route to achieving therapeutic metabolic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively promote browning of WAT, as evidenced by reduced cell size and increased cell number, and UCP1 immunochemistry analysis, demonstrating their potential in treating metabolic disorders with reduced side effects.
Implementation Method 1
BAT can dissipate lipids to provide heat in a process called thermogenesis
Implementation Method 2
UCP1 uncouples oxidative phosphorylation in mitochondria to dissipate the electrochemical gradient as heat
Data Source
Figure 1
AI summary
The present invention provides a compound for inducing browning of white adipose tissue in vitro and in vivo of formula I, the preparation method thereof, as well as a composition comprising the same. Further, the present invention also relates to the use of the compound and the method to treat metabolic disorders, such as obesity and diabetes.